A Study of Olaparib and Durvalumab in Prostate Cancer
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the combination of olaparib and durvalumab are
better than the standard of care for treating prostate cancer.